Peptomyc is pioneering the development of innovative cancer treatments through the use of mini-protein therapeutics that specifically target the MYC oncogene, a critical driver of cancer proliferation and survival. Their lead product, OMO-103, is a first-in-class MYC inhibitor derived from the Omomyc peptide, which has demonstrated significant efficacy in preclinical models and has successfully completed a Phase I clinical trial, showcasing its safety and anti-tumor activity. The unique mechanism of action of these cell-penetrating mini-proteins allows for targeted eradication of cancer cells while minimizing damage to healthy tissues, addressing a significant unmet need in cancer therapy.

The technology behind Peptomyc's approach is rooted in extensive research conducted by Dr. Laura Soucek and her team at the Vall d’Hebron Institute of Oncology. The Omomyc mini-protein not only inhibits MYC but also possesses remarkable cell-penetrating properties, enabling it to effectively enter cells and exert its therapeutic effects. Peptomyc's ongoing clinical trials, including a Phase Ib study in combination with standard treatments for pancreatic cancer, aim to further validate the utility of OMO-103 across various cancer types. The company is also exploring the potential for developing therapies targeting brain metastases, thereby expanding the scope of their innovative cancer treatments.

Spain

Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research on Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.

Peptomyc

Company Details